Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment.
Bcl-xL
Melanoma
Tumor-associated macrophages
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
24 Jul 2023
24 Jul 2023
Historique:
received:
23
02
2023
accepted:
16
06
2023
medline:
27
7
2023
pubmed:
25
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
Macrophages take center stage in the tumor microenvironment, a niche composed of extracellular matrix and a heterogeneous group of cells, including immune ones. They can evolve during tumor progression and acquire Tumor-Associated Macrophage (TAMs) phenotype. The release of cytokines by tumor and stromal cells, influence the secretion of cytokines by TAMs, which can guarantee tumor progression and influence the response to therapy. Among all factors able to recruit and polarize macrophages, we focused our attention on Bcl-xL, a multifaceted member of the Bcl-2 family, whose expression is deregulated in melanoma. It acts not only as a canonical pro-survival and anti-apoptotic protein, but also as a promoter of tumor progression. Human melanoma cells silencing or overexpressing Bcl-xL protein, THP-1 monocytic cells and monocyte-derived macrophages were used in this study. Protein array and specific neutralizing antibodies were used to analyze cytokines and chemokines secreted by melanoma cells. qRT-PCR, ELISA and Western Blot analyses were used to evaluate macrophage polarization markers and protein expression levels. Transwell chambers were used to evaluate migration of THP-1 and monocyte-derived macrophages. Mouse and zebrafish models were used to evaluate the ability of melanoma cells to recruit and polarize macrophages in vivo. We demonstrated that melanoma cells overexpressing Bcl-xL recruit macrophages at the tumor site and induce a M2 phenotype. In addition, we identified that interleukin-8 and interleukin-1β cytokines are involved in macrophage polarization, and the chemokine CCL5/RANTES in the macrophages recruitment at the tumor site. We also found that all these Bcl-xL-induced factors are regulated in a NF-kB dependent manner in human and zebrafish melanoma models. Our findings confirmed the pro-tumoral function of Bcl-xL in melanoma through its effects on macrophage phenotype.
Sections du résumé
BACKGROUND
BACKGROUND
Macrophages take center stage in the tumor microenvironment, a niche composed of extracellular matrix and a heterogeneous group of cells, including immune ones. They can evolve during tumor progression and acquire Tumor-Associated Macrophage (TAMs) phenotype. The release of cytokines by tumor and stromal cells, influence the secretion of cytokines by TAMs, which can guarantee tumor progression and influence the response to therapy. Among all factors able to recruit and polarize macrophages, we focused our attention on Bcl-xL, a multifaceted member of the Bcl-2 family, whose expression is deregulated in melanoma. It acts not only as a canonical pro-survival and anti-apoptotic protein, but also as a promoter of tumor progression.
METHODS
METHODS
Human melanoma cells silencing or overexpressing Bcl-xL protein, THP-1 monocytic cells and monocyte-derived macrophages were used in this study. Protein array and specific neutralizing antibodies were used to analyze cytokines and chemokines secreted by melanoma cells. qRT-PCR, ELISA and Western Blot analyses were used to evaluate macrophage polarization markers and protein expression levels. Transwell chambers were used to evaluate migration of THP-1 and monocyte-derived macrophages. Mouse and zebrafish models were used to evaluate the ability of melanoma cells to recruit and polarize macrophages in vivo.
RESULTS
RESULTS
We demonstrated that melanoma cells overexpressing Bcl-xL recruit macrophages at the tumor site and induce a M2 phenotype. In addition, we identified that interleukin-8 and interleukin-1β cytokines are involved in macrophage polarization, and the chemokine CCL5/RANTES in the macrophages recruitment at the tumor site. We also found that all these Bcl-xL-induced factors are regulated in a NF-kB dependent manner in human and zebrafish melanoma models.
CONCLUSIONS
CONCLUSIONS
Our findings confirmed the pro-tumoral function of Bcl-xL in melanoma through its effects on macrophage phenotype.
Identifiants
pubmed: 37488586
doi: 10.1186/s13046-023-02735-9
pii: 10.1186/s13046-023-02735-9
pmc: PMC10364435
doi:
Substances chimiques
Cytokines
0
bcl-X Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : ID24315
Organisme : Banca d'Italia
ID : Contributo Liberale
Informations de copyright
© 2023. The Author(s).
Références
Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9271-E9279
pubmed: 29078276
Theranostics. 2022 Feb 28;12(5):2427-2444
pubmed: 35265218
Int J Mol Sci. 2021 Mar 09;22(5):
pubmed: 33803452
Br J Cancer. 1988 Feb;57(2):174-7
pubmed: 2833921
Melanoma Res. 2021 Oct 1;31(5):476-481
pubmed: 34284461
Blood. 2011 Jan 27;117(4):e49-56
pubmed: 21084707
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
PLoS One. 2012;7(12):e50946
pubmed: 23284651
Clin Cancer Res. 2011 Aug 15;17(16):5226-32
pubmed: 21576085
Front Immunol. 2014 Mar 26;5:127
pubmed: 24723924
Front Immunol. 2020 Aug 18;11:1988
pubmed: 33013851
Cancer Cell. 2011 Apr 12;19(4):512-26
pubmed: 21481792
J Neurochem. 2008 Nov;107(3):871-82
pubmed: 18786178
Oncoimmunology. 2015 Dec 10;5(3):e1089381
pubmed: 27141346
J Cancer Res Clin Oncol. 2021 Jul;147(7):1993-2001
pubmed: 33770254
Br J Cancer. 2022 Oct;127(6):1142-1152
pubmed: 35725813
J Control Release. 2016 Feb 10;223:165-177
pubmed: 26742942
Mol Cancer Res. 2011 Nov;9(11):1537-50
pubmed: 21954434
Front Pharmacol. 2019 Oct 23;10:1255
pubmed: 31708781
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32269145
In Vivo. 2002 Nov-Dec;16(6):471-7
pubmed: 12494891
J Leukoc Biol. 2022 Dec;112(6):1369-1370
pubmed: 35766198
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
DNA Cell Biol. 2012 Mar;31(3):280-9
pubmed: 21895511
Oncol Lett. 2018 Apr;15(4):5399-5404
pubmed: 29552183
Immunity. 2021 May 11;54(5):903-915
pubmed: 33979587
Int J Exp Pathol. 2006 Jun;87(3):163-76
pubmed: 16709225
Zebrafish. 2014 Apr;11(2):85-97
pubmed: 24428354
PLoS One. 2015 Oct 07;10(10):e0138949
pubmed: 26445458
Dev Biol. 2007 Apr 15;304(2):811-24
pubmed: 17335798
J Immunol. 2000 May 15;164(10):5352-61
pubmed: 10799898
Elife. 2015 Jul 08;4:e07288
pubmed: 26154973
Int J Oncol. 2022 May;60(5):
pubmed: 35362544
J Immunol. 2005 Jul 1;175(1):461-8
pubmed: 15972680
FASEB J. 2006 Dec;20(14):2570-2
pubmed: 17060399
Int Immunol. 2001 Dec;13(12):1479-87
pubmed: 11717189
Mol Cancer Res. 2007 Aug;5(8):761-71
pubmed: 17699103
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Cell Death Dis. 2019 Dec 4;10(12):918
pubmed: 31801938
Int J Med Sci. 2020 May 18;17(9):1257-1268
pubmed: 32547321
Int J Cancer. 2018 Feb 1;142(3):584-596
pubmed: 28949016
Cancer Res. 2007 Jan 1;67(1):122-9
pubmed: 17210691
Cell Biosci. 2021 Jan 6;11(1):2
pubmed: 33407883
Adv Exp Med Biol. 2014;816:437-69
pubmed: 24818733
Cancer Cell Int. 2020 May 25;20:195
pubmed: 32508531
Adv Mater. 2019 Dec;31(51):e1904364
pubmed: 31659802
Blood. 2011 Nov 17;118(20):5498-505
pubmed: 21972293
Mol Hum Reprod. 2001 Aug;7(8):787-90
pubmed: 11470867
Oncoimmunology. 2016 Jan 4;5(4):e1122157
pubmed: 27141406
Drug Discov Today. 2021 May;26(5):1126-1135
pubmed: 33545382
PLoS One. 2014 Jun 12;9(6):e99568
pubmed: 24924428
Cells. 2020 May 21;9(5):
pubmed: 32455818
Cell Death Dis. 2017 Dec 13;8(12):3216
pubmed: 29238043
Front Immunol. 2020 Aug 21;11:1849
pubmed: 32973762
Genes Dev. 2008 Mar 1;22(5):559-74
pubmed: 18316475
Bio Protoc. 2015 May 11;5(21):
pubmed: 27034969
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Int J Cancer. 2000 Apr 15;86(2):188-96
pubmed: 10738245
J Exp Clin Cancer Res. 2019 Sep 13;38(1):405
pubmed: 31519199
Cancer Metastasis Rev. 2012 Dec;31(3-4):621-32
pubmed: 22684365